Vimian Group (VIMIAN) Aperçu de l'action
Vimian Group AB (publ) est présent dans le secteur de la santé animale dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 4/6 |
| Performances passées | 4/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour VIMIAN à partir de nos contrôles de risques.
VIMIAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Vimian Group AB (publ) Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | SEK 29.30 |
| Plus haut sur 52 semaines | SEK 46.00 |
| Plus bas sur 52 semaines | SEK 24.18 |
| Bêta | 1.19 |
| Variation sur 1 mois | -1.84% |
| Variation sur 3 mois | 9.90% |
| Variation sur 1 an | -24.76% |
| Variation sur 3 ans | 3.31% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | -63.78% |
Nouvelles et mises à jour récentes
Mise à jour du récit • May 06
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.
Mise à jour du récit • Apr 17
VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential
Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.Mise à jour du récit • Apr 03
VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential
Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.Recent updates
Mise à jour du récit • May 06
VIMIAN: Margin Execution And Governance Changes Will Support Future Upside Potential
Analysts now see fair value for Vimian Group at about SEK 35, up from roughly SEK 34, even though the latest Street research includes a reduced price target to SEK 25 from SEK 27. This reflects updated views on revenue growth, margins, the appropriate discount rate and future P/E assumptions.Mise à jour du récit • Apr 17
VIMIAN: Higher Discount Rate Will Constrain Future Upside Potential
Analysts have trimmed their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated views on discount rates, growth and profitability assumptions. Analyst Commentary Bearish analysts are signaling a more cautious stance on Vimian Group, with the latest move being a reduction in the price target to SEK 25 from SEK 27.Mise à jour du récit • Apr 03
VIMIAN: Margin Execution And New Bylaws Will Support Future Upside Potential
Analysts have reduced their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on margins and valuation multiples that result in a slightly adjusted fair value model. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with the updated SEK 25 price target reflecting revised assumptions on margins and valuation multiples rather than a shift in rating.Mise à jour du récit • Mar 20
VIMIAN: Lower Price Outlook And Execution Risks Will Shape Fair Value Balance
Analysts have trimmed their price target for Vimian Group to SEK 25 from SEK 27, citing updated assumptions on growth, margins and valuation multiples that align the target more closely with recent research views. Analyst Commentary Recent research reflects a cautious tone around Vimian Group, with the latest move being a trim in the price target to SEK 25 from SEK 27.Mise à jour du récit • Mar 05
VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects
Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.
Mise à jour du récit • Feb 19
VIMIAN: Reset Expectations Will Highlight Execution Under New CEO Appointment
Analysts have trimmed their fair value estimate and price target on Vimian Group to SEK 27 from SEK 37, reflecting updated assumptions around slightly higher growth, a lower profit margin profile and a higher expected P/E multiple, which together point to a more cautious risk return trade off. Analyst Commentary Bullish analysts looking at Vimian Group are focusing less on the headline downgrade and more on what the revised SEK 27 target implies for execution, valuation and growth expectations from here.Article d’analyse • Feb 16
Vimian Group AB (publ) (STO:VIMIAN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Vimian Group AB (publ) ( STO:VIMIAN ) had a good week, as its shares rose 5.9% to close at kr27.84...Article d’analyse • Feb 05
Is Vimian Group (STO:VIMIAN) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Mise à jour du récit • Feb 05
VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade
Narrative update Analysts have trimmed their price expectations for Vimian Group, with the updated fair value estimate easing from SEK 36.92 to SEK 33.76, as some now see lower future P/E assumptions and have adopted more cautious views similar to the recent SEK 27 price target cut in Street research. Analyst Commentary Recent research updates on Vimian Group have taken a more cautious tone, with the shift to an Underweight rating and a price target of SEK 27, down from SEK 37.Mise à jour du récit • Jan 22
VIMIAN: Rebased Expectations Will Spotlight Execution Under New Leadership Transition Narrative
Analysts have reduced their fair value estimate for Vimian Group to SEK 41.36 from SEK 41.97, citing slightly higher discount rate assumptions and updated sector views. This follows a recent cut in the Street price target to SEK 27 from SEK 37.Mise à jour du récit • Jan 08
VIMIAN: Rebased Expectations Will Highlight Execution On M&A-Led Expansion Narrative
Analysts have lowered their fair value estimate for Vimian Group from SEK 51.65 to SEK 41.97, citing more cautious assumptions on revenue growth and valuation multiples in line with recent price target cuts, including the move to SEK 27 from SEK 37 in Barclays' 2026 industry outlook. Analyst Commentary Recent research points to a more cautious stance on Vimian Group, with fair value and price targets recalibrated to reflect updated assumptions on revenue growth and sector valuation.Article d’analyse • Jan 08
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Mise à jour du récit • Dec 23
VIMIAN: Downgrade And New CEO Will Shape Medium Term Risk Outlook
Analysts have lowered their price target on Vimian Group from approximately SEK 37 to around SEK 27. This reflects more cautious assumptions on growth, profitability, and valuation multiples in line with a more conservative sector outlook for 2026.Mise à jour du récit • Dec 09
VIMIAN: Future Leadership Will Drive Cash Flow Execution Upside Despite Sector Downgrade
Analysts have trimmed their price target on Vimian Group by SEK 10 to SEK 27. This reflects slightly higher discount rate assumptions and more conservative long term valuation multiples for the sector.Mise à jour du récit • Nov 25
VIMIAN: Future Leadership and Expanded Acquisitions Will Drive Market Resilience
Narrative Update on Vimian Group Analysts have lowered Vimian Group's fair value estimate from SEK 38.90 to SEK 36.97. This revision is attributed to reduced revenue growth expectations, a higher discount rate, and a more cautious industry outlook reflected in recent research.Article d’analyse • Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price
Key Insights The projected fair value for Vimian Group is kr43.69 based on 2 Stage Free Cash Flow to Equity Vimian...Mise à jour du récit • Sep 05
Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare
Ongoing execution challenges in MedTech, anticipated organic growth slowing to 5% in 2025, and required recovery in orthopedics have led analysts to adopt a more cautious outlook and maintain Vimian Group's price target at SEK38.90. Analyst Commentary Ongoing execution challenges in the MedTech segment are impacting overall group momentum.Article d’analyse • Aug 14
Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
OM:VIMIAN 1 Year Share Price vs Fair Value Explore Vimian Group's Fair Values from the Community and select yours...Article d’analyse • Jun 17
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • Jun 02
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)
Key Insights Vimian Group's estimated fair value is kr55.41 based on 2 Stage Free Cash Flow to Equity Vimian Group's...Article d’analyse • May 15
Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely
With a median price-to-sales (or "P/S") ratio of close to 4.6x in the Medical Equipment industry in Sweden, you could...Article d’analyse • Mar 05
Is Vimian Group (STO:VIMIAN) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • Feb 21
Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem
Unsurprisingly, Vimian Group AB (publ)'s ( STO:VIMIAN ) stock price was strong on the back of its healthy earnings...Article d’analyse • Feb 14
A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
Key Insights The projected fair value for Vimian Group is kr54.92 based on 2 Stage Free Cash Flow to Equity Current...
Nouveau récit • Feb 09
iM3 Acquisition Will Expand Presence In Veterinary Dental Space
Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.Article d’analyse • Dec 16
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Article d’analyse • Aug 31
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%
Vimian Group AB (publ) ( STO:VIMIAN ) shareholders have had their patience rewarded with a 27% share price jump in the...Article d’analyse • Aug 17
Is Vimian Group (STO:VIMIAN) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Article d’analyse • Apr 18
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Vimian Group AB (publ)'s ( STO:VIMIAN ) robust earnings report didn't manage to move the market for its stock. Our...Article d’analyse • Apr 09
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vimian Group fair value estimate is kr55.14 Vimian Group's...Article d’analyse • Feb 13
Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Article d’analyse • Jan 08
Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues
Vimian Group AB (publ)'s ( STO:VIMIAN ) price-to-sales (or "P/S") ratio of 3.6x might make it look like a buy right now...Article d’analyse • Dec 03
Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching
While Vimian Group AB (publ) ( STO:VIMIAN ) might not be the most widely known stock at the moment, it saw a...Article d’analyse • Nov 01
There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Rendement pour les actionnaires
| VIMIAN | SE Medical Equipment | SE Marché | |
|---|---|---|---|
| 7D | -2.7% | 6.1% | 1.9% |
| 1Y | -24.8% | -4.0% | 12.3% |
Rendement vs Industrie: VIMIAN a sous-performé le secteur Swedish Medical Equipment qui a rapporté -4 % au cours de l'année écoulée.
Rendement vs marché: VIMIAN a sous-performé le marché Swedish qui a rapporté 12.3 % au cours de l'année écoulée.
Volatilité des prix
| VIMIAN volatility | |
|---|---|
| VIMIAN Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.7% |
Cours de l'action stable: VIMIAN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Swedish.
Volatilité au fil du temps: La volatilité hebdomadaire de VIMIAN ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2020 | 1,300 | Alireza Tajbakhsh | vimian.com |
Vimian Group AB (publ) est présent dans le secteur de la santé animale à l'échelle mondiale. Ses activités s'articulent autour des segments Specialty Pharma, MedTech, Diagnostics et Veterinary Services. La société propose des diagnostics exclusifs, des traitements avec ou sans ordonnance pour les soins préventifs et le traitement des maladies chroniques chez les animaux de compagnie sous la marque Nextmune, ainsi que des solutions moléculaires et immunodiagnostiques utilisées par les laboratoires pour des applications vétérinaires spécifiques, en particulier sur les marchés de la santé du bétail et des animaux de compagnie, sous la marque Indical Bioscience.
Vimian Group AB (publ) Résumé des fondamentaux
| VIMIAN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | SEK 15.51b |
| Bénéfices(TTM) | SEK 399.86m |
| Recettes(TTM) | SEK 4.71b |
38.8x
Ratio P/E3.3x
Ratio P/SLe site VIMIAN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| VIMIAN compte de résultat (TTM) | |
|---|---|
| Recettes | €433.60m |
| Coût des recettes | €134.40m |
| Marge brute | €299.20m |
| Autres dépenses | €262.40m |
| Les revenus | €36.80m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 17, 2026
| Résultat par action (EPS) | 0.07 |
| Marge brute | 69.00% |
| Marge bénéficiaire nette | 8.49% |
| Ratio dettes/capitaux propres | 31.5% |
Quelles ont été les performances à long terme de VIMIAN?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 17:48 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Vimian Group AB (publ) est couverte par 10 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Jonathon Unwin | Barclays |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |